

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
2 October 2003 (02.10.2003)

PCT

(10) International Publication Number
WO 03/080566 A2(51) International Patent Classification⁷: C07C 259/06,
C07D 207/46, C07C 59/347, C07K 5/06, C07C 309/17,
C07F 5/02, A61K 31/194, 31/16, 31/33Peter, John [GB/GB]; Wellcome Trust Centre for Human
Genetics, Roosevelt Drive, Oxford OX3 7BN (GB).

(21) International Application Number: PCT/GB03/01239

(74) Agents: ELLIS-JONES, Patrick, George, Armine et al.;
J.A. Kemp & Co., 14 South Square, Gray's Inn, London
WC1R 5JJ (GB).

(22) International Filing Date: 21 March 2003 (21.03.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0206711.4 21 March 2002 (21.03.2002) GB(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE,
SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ,
VC, VN, YU, ZA, ZM, ZW.(71) Applicant (*for all designated States except US*): ISIS IN-
NOVATION LIMITED [GB/GB]; Ewert House, Ewert
Place, Summertown, Oxford OX2 7SG (GB).(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW),
Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM),
European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE,
ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO,
SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM,
GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).






(72) Inventors; and

(75) Inventors/Applicants (*for US only*): SCHOFIELD,
Christopher, Joseph [GB/GB]; Dyson Perrins Labora-
tory, University of Oxford, South Parks Road, Oxford
OX1 3QY (GB). MAXWELL, Patrick, Henry [GB/GB];
Imperial College of Science, Technology & Medicine,
Hammersmith Campus, Du Cane Road, London W12 0NN
(GB). PUGH, Christopher, William [GB/GB]; University
of Oxford, Wellcome Trust Centre for Human Genetics,
Roosevelt Drive, Oxford OX3 7BN (GB). RATCLIFFE,

Published:

— without international search report and to be republished
upon receipt of that reportFor two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HIF HYDROXYLASE INHIBITORS



(57) Abstract: The invention provides a compound of one of the formulae (A), (B), (C), (D), (E), (F) as herein defined, or a salt thereof, for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.

HIF HYDROXYLASE INHIBITORS

Field of Invention

The present invention relates to compounds which modulate 2OG (2-oxoglutarate) dependent oxygenases, in particular prolyl hydroxylases. These may be useful as modulators of HIF (hypoxia inducible factor) alpha (HIF- α) prolyl hydroxylase.

Background of Invention

The transcription factor HIF (hypoxia inducible factor) system is a key regulator of responses to hypoxia, occupying a central position in oxygen homeostasis in a wide range of organisms. A large number of transcriptional targets have been identified, with critical roles in angiogenesis, erythropoiesis, energy metabolism, inflammation, vasomotor function, and apoptotic/proliferative responses. The system is essential for normal development, and plays a key role in pathophysiological responses to ischaemia/hypoxia. HIF is also important in cancer, in which it is commonly upregulated, and has major effects on tumour growth and angiogenesis. The HIF DNA binding complex consists of a heterodimer of α and β subunits. Regulation by oxygen occurs through hydroxylation of the α -subunits, which are rapidly destroyed by the proteasome in oxygenated cells. This involves binding of HIF- α -subunits by the von Hippel-Lindau tumour suppressor protein (pVHL), with pVHL acting as the, or part of the, recognition component for a ubiquitin ligase that promotes ubiquitin dependent proteolysis through interaction with a specific sequence or sequences in HIF- α -subunits. In hypoxia, this process is suppressed, so stabilizing HIF- α and permitting transcriptional activation via the HIF α , β .

Disclosure of the Invention

In our British Application No. 0118952.1 we disclose a polypeptide comprising:

- (a) the amino acid sequence of SEQ ID NO: 2, 4 or 6 having HIF hydroxylase activity;
- (b) a variant thereof having at least 60% identity to the amino acid

sequence of SEQ ID NO: 2, 4 or 6 and having hydroxylase activity; or

(c) a fragment of either thereof having HIF- α hydroxylase activity.

Preferably, the polypeptides have prolyl hydroxylase activity and require Fe(II) for activity.

5 They are related by sequence to non-haem oxygenases for which crystal structures are known, e.g. proline-3-hydroxylase (Clifton et al, Eur. J. Biochem, 2001, 268, 6625-6636).

It also discloses polynucleotides which encode the polypeptides as well as expression vectors comprising the polynucleotide and antibodies capable of
10 specifically binding the polypeptide. We also disclose assays for identifying modulators of the activity of the HIF hydroxylase as well as the use of modulators such as inhibitors of the activity of the peptides in the treatment of a condition or disease associated with altered HIF levels with respect to healthy (or normal) levels, and the treatment of conditions where an alteration in the HIF levels or activity
15 would be beneficial.


Inhibitors of the 2-OG dependent enzyme collagen prolyl-4-hydroxylase (CPH) are well known in the art and have been previously proposed for use in the treatment of lung fibrosis, skin fibrosis (scleroderma), atherosclerosis and other conditions associated with collagen biosynthesis. Inhibitors of para-
20 hydroxyphenylpyruvate oxygenase (a non-haem oxygenase employing ferrous iron as a co-factor) such as triketones are used as herbicides (Lee D. et al (1998) Pestic. Sci. 54(4) 377-384). We have disclosed that certain of these CPH inhibitors (and other components) also inhibit the biological (i.e. HPH) activity of an PHD polypeptide. A CPH inhibitor or modified CPH inhibitor which inhibits the biological activity of an
25 PHD polypeptide may be used in the treatment of a condition associated with reduced or suboptimal HIF levels or activity, or a condition in which an increase in HIF levels or activity may be beneficial, for example ischaemia, wound healing, auto-, allo-, and xeno- transplantation, systemic high blood pressure, cancer, inflammatory disorders, and metabolic disorders.

30 Various methods and uses of modulators which inhibit, potentiate, increase or stimulate hydroxylation of HIF- α by an PHD polypeptide are disclosed. The purpose

of disruption, interference with or modulation of the hydroxylation of HIF-1 α by a PHD polypeptide may be to modulate cellular functions such as angiogenesis, erythropoiesis, energy metabolism, inflammation, matrix metabolism, vasomotor function, and apoptotic/proliferative responses and pathophysiological responses to ischaemia/hypoxia, all of which are mediated by HIF α as discussed above.


Compounds which modulate 2OG oxygenases, in particular CPH may be useful as modulators of HIF prolyl hydroxylase, or may be used as 'lead' compounds which may be modified and/or optimised to develop modulators of HIF prolyl hydroxylase, in particular selective modulators are described.

10 Some of these compounds generally possess the formula:




where the group R^1 is capable of forming an electrostatic interaction with the sidechain of the arginine residue which, together with other residues, binds the 5-carboxylate of 2-oxoglutarate during catalysis, $A*B$ is a chain of two atoms which are, independently, carbon, oxygen, nitrogen or sulphur, which chain can be functionalised, y is 0 or 1 and $C*D$ is a chain of two atoms which are, independently, carbon, oxygen, nitrogen, or sulphur, which chain can be functionalised, A , B , C and D being linked to one another by a single and/or double and/or triple bond such that when y is 0 or 1 at least one of the atoms of which is capable of chelating with a metal group and when y is 1 said chain is attached to R^2 which is capable of chelating with a metal group. Generally at least one of A , B , C and D is not carbon. Typical chains include $C-N-C-C$ and $C-O-C-C$ and $C-C-C=O$. The chain atoms can form part of a ring.

New classes of modulators of HIF prolyl hydroxylase have been found, according to the present invention. These possess the following formulae (A) to (F)




where each of R¹ and R⁵ is independently H, OH, SH, a branched or straight C₁ to C₆


alkyl chain optionally containing 1 or more eg. 2 N, S, O or P chain atoms, especially methyl, which can be functionalised, any amino acid side chain, such as alanine, phenylalanine, valine and glutamic acid, a 4 to 7 membered heterocyclic ring optionally containing 1 or 2 N, S, O or P atoms or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms which may be fused to another ring or a said alkyl chain substituted by a said aromatic ring, such as aryloxy alkyl, A¹ is CH₂ or O, and each of R² and R³ is independently be H, OH, a branched or straight C₁ to C₆ alkyl chain optionally containing 1 or more eg. 2 N, S, O or P chain atoms which can be functionalised, optionally with 1, 2, 3, 4 or 5 halo substitutions, a 4 to 7 membered heterocyclic ring optionally containing 1 or 2 N, S, O or P atoms, or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms which may be fused to another ring or a said alkyl chain substituted by a said aromatic ring,




wherein R² is as defined above, --- is a single bond and T is CH₂ or C=O, or --- is a double bond and T is CH; A² is H or -XCO₂R⁴; X is a single bond or a branched or straight C₁ to C₆ alkyl chain, optionally containing 1 or more eg. 2 N, S, O or P chain atoms and optionally substituted by eg. halo, OH, NHR² or NHCOR⁴ where R² and R⁴ are as defined above and R⁴ represents H, a branched or straight chain C₁ to C₆ alkyl group optionally containing 1 or more eg. 2 N, S, O or P chain atoms, a 4 to 7 membered heterocyclic ring, optionally containing 1 or 2 N, S, O or P atoms, or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms, which may be fused to another ring, or a salt thereof,



where each X which may be the same or different is NH, NRⁿ, where Rⁿ is OH, a branched or straight C₁ to C₆ alkyl chain optionally containing 1 or more eg. 2 N, S, O or P chain atoms which can be functionalised, or O i.e. XR¹ is typically OH or O-alkyl having a branched or straight C₁ to C₆ alkyl chain, especially MeO,
 5 each Y, which may be the same or different, is O or S and each R¹, which may be the same or different, is as defined above,




10 where m is 0 or 1, Q represents (R¹R⁶)_xZ where x is 0, 1 or 2, R¹ is as defined above and R⁶ is as defined for R¹, and Z is P=O(OH)₂, B(OH)₂ or SO₃H, or a salt thereof, typically a sodium salt, or



where each R¹, which are the same or different, is as defined above; R¹¹ represents OH or R¹⁰ NH where R¹⁰ is HO, R¹CO or HOOC(X)_x wherein R¹ is as defined above,
 20 x is 0 or 1 and X is R¹R¹C wherein each R¹, which are the same or different, is as defined above; or R¹⁰ is an amino acid residue H₂N (R¹R¹C) CO - wherein each R¹, which are the same or different, is as defined above; n is 1 or 2 and R¹² is H or straight or branched C₁ to C₆ alkyl; or a salt thereof. Typically X is CH₂ or CHOH.

Another aspect of the invention concerns analogues of 2-oxoglutarate that act
 25 as improved (relative to 2-oxoglutarate) co-substrates for the HIF hydroxylases. Such a compound is 3-fluoro 2-oxoglutarate. Assays in which this compound replaces 2-oxoglutarate demonstrate a higher level of HIF hydroxylation than observed when using 2-oxoglutarate under analogous conditions.

These analogues possess the formula:



5 wherein each of Z^1 and Z^2 is independently hydrogen, SH or an electron withdrawing group such as halogen, preferably fluorine, or alkoxy such as methoxy, and R^{12} is as defined above, or a salt thereof. Preferably one of Z^1 and Z^2 is hydrogen and the other is fluorine (3-F-2-OG).

Accordingly the present invention provides a compound of formula (A) to
 10 (F) for use in the treatment of a condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial, as well as the use of a compound of formula (A) to (F) in the manufacture of a medicament for the treatment of such a condition.

The said alkyl groups and chains are typically functionalised by alcohol,
 15 fluorine, thiol, a carboxylic acid, phosphonic or phosphinic acid, sulphonic acid or other chelating group, in the case of the chains typically via an alkyl group.

In the formulae described herein, a branched or straight C_1 to C_6 alkyl chain may be a methyl, ethyl, propyl, butyl, iso-butyl, *tert*-butyl, pentyl, neopentyl, *tert*-pentyl or a primary, secondary or tertiary hexyl group. Hetero atoms such as O, S, N
 20 and P may replace one or more of the carbon atoms. Preferably the alkyl groups are methyl, the preferred heterocyclic rings are pyrrolidine and tetrahydropyran and the preferred aromatic rings are benzene, naphthalene and pyridine.

Typically, each of R^1 and R^5 is independently H, OH, a branched or straight C_1 to C_6 alkyl chain optionally containing 1 or more N, S, O or P chain atoms, which
 25 can be functionalised, any amino acid side chain, a 4 to 7 membered heterocyclic ring optionally containing 1 or 2 N, S, O or P atoms or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms which may be fused to another ring or a said alkyl chain substituted by a said aromatic ring.

Typically, A^1 is CH_2 .

30 Typically, A^2 is $-\text{XCO}_2\text{R}^4$.

Typically, R^{11} represents R^{10}NH where R^{10} is R^1CO or $\text{HOOC}(\text{X})_x$ wherein

R^1 is as defined above, x is 0 or 1 and X is R^1R^1C wherein each R^1 , which are the same or different, is as defined above; or R^{10} is an amino acid residue $H_2N(R^1R^1C)CO-$ wherein each R^1 , which are the same or different, is as defined above.

Typically, each of Z^1 and Z^2 is independently hydrogen or an electron
5 withdrawing group.

Typically, in the compounds of formula (F), R^{12} is H. Alternatively, R^{12} may be straight or branched C_1 to C_6 alkyl.

The compounds of formula (A) are hydroxamates. Preferred compounds include those where R^5 is aryloxyalkyl, especially oxyloxymethyl such as
10 phenyloxymethyl or phenylalkyloxymethyl, especially benzyloxymethyl or substituted benzyloxymethyl such as p-hydroxy benzyloxymethyl and/or where R^2 and/or R^3 is $HOCH_2$.

Typical compounds include N-phenoxy-acetyl-(L)-alanine-hydroxamide (Is41) and the corresponding (D) isomer (Is43) as well as the corresponding tyrosine
15 derivatives (Is44 and 45) and L- and D-phenylglycine derivatives (Is46 and 47), along with benzo hydroxamic acid and N-phenoxyacetyl-D-phenylalanine hydroxamic acid (Is42).

These compounds can generally be prepared following the method of Walter et al., Tetrahedron 1997, 53, 7275-7290 and Biorg. Chem 1999, 27, 35-40.

20 The compounds of formula (B) are cyclic hydroxamates. Preferred compounds are those where X is a single bond or methyl and/or R^2 is H or phenylalkyl, especially benzyl and/or R^4 is H or methyl. Typical compounds include (1-hydroxy-2, 5-dioxo-pyrrolidin-3-yl) acetic acid (Is52), (1-hydroxy-2, 5-dioxo-pyrrolidin-3-yl) carboxylic acid (ANU 2) and its N-benzoyloxy derivative (ANU 1)
25 along with (1-benzyloxy-2, 5-dioxo-pyrrolidin-3-yl) acetic acid (Is50) and the corresponding methyl ester (Is64), and N-hydroxy succinimide (C1). Note that Is52 ($R^2=H$, $T=C=O$, $X=CH_2$, $R^4=H$) is highly active reflecting its structural analogy with 2-oxoglutarate. These compounds can be prepared using the general procedure of Schlicht et al. (US 4446038).

30 The compounds of formula (C) are analogues of 2-oxoglutarate or oxalyl derivatives of hydroxyacetate and mercapto acetic acid. Preferred compounds

include those where X is O and/or R¹ is H or methyl. Typical compounds include dimethyl oxalylglycolate (Is10) as well as its free acid (Is14) and dimethyl oxalylthioglycolate (Is11). These compounds can be prepared following Franklin et al., J. Med. Chem 1992, 35, 2652-2658 or Kwon et al., J. Am. Chem. Soc. 1989, 111, 1854-1860.

The compounds of formula (D) are carboxylic acids which possess a phosphonic, sulphonic or boronic acid group as well as salts of these. Typically R' and R⁶ are hydrogen. Preferred compounds include the phosphoric acids where x is 0, 1 or 2 (C3, 4 and 5, respectively) as well as disodium 3-sulpho-propionate (Is63) and its free acid, and 3-borono-propionic acid (Is62).

The compounds of formula (E) are N-acylated amino acids or polycarboxylic acids. Typical compounds are those where R¹ is H, and/or R¹² is H or ethyl. When R¹¹ represents R¹⁰NH the compounds are typically dipeptides such that R¹⁰ is an acyl group of a natural amino acid such as glycine. Typical preferred such compounds include Asp-Gly (C18), cyclo (Asp-Gly) (C19), beta-Asp-Gly (C20), Glu-Gly (C21) and Z-Glu-Gly (C22). Other typical compounds include those where R¹⁰ is acetyl or benzoyl such as the N-acetylated derivatives of L-aspartic acid (C6) and of L-glutamic acid (C7) i.e. R¹⁰ is acetyl and N-benzoylated derivatives of glutamic acid (C15 and Is90) i.e. R¹⁰ is benzoyl. Other typical compounds include those where R¹¹ is -NHOH such as diethyl 2-(hydroxylamino)-glutarate (Is51 being the racemic form of this compound) and those where R¹¹ is OH such as 2-hydroxyglutaric acid (Is57). When R¹¹ is HOOC(X)x, X is especially CH² or CHOH. The compounds are typically citric acid (C12), tricarballic acid (C13) and succinic acid as well as the tri-methyl ester of ethane tricarboxylic acid (Is72).

The compounds of formula (F) are analogues of 2-oxoglutarate. Preferred compounds include 3-fluoro-2-oxoglutarate compounds (i.e. Z¹ is H and Z² is F) such as 3-fluoro-2-oxoglutaric acid (Is18) and the corresponding dimethyl ester (Is19).

The compounds which are acids can be present in the form of salts, such as sodium salts.

For therapeutic treatment, the compound may be used in combination with any other active substance, e.g. for anti-tumour therapy another anti-tumour

compound or therapy, such as radiotherapy or chemotherapy.

Generally, the modulator is provided in an isolated and/or purified form, i.e. substantially pure. This may include being in a composition where it represents at least about 90% active ingredient, more preferably at least about 95%, more preferably at least about 98%. Any such composition may, however, include inert carrier materials or other pharmaceutically and physiologically acceptable excipients, such as those required for correct delivery, release and/or stabilisation of the active agent. As noted below, a composition according to the present invention may include in addition to a modulator compound as disclosed, one or more other molecules of therapeutic use, such as an anti-tumour agent.

In general they take the form of compositions wherein the compound is in a mixture with a pharmaceutically acceptable carrier or diluent. The carrier may be liquid, e.g. saline, ethanol, glycerol and mixtures thereof, or solid, e.g. in the form of a tablet, or in a semi-solid form such as a gel formulated as a depot formulation or in a transdermally administerable vehicle, such as a transdermal patch. The modulator compound or composition comprising it may be formulated as the coating of a coated stent.

The invention further provides a method of treatment which includes administering to a patient compound as defined above. Exemplary purposes of such treatment are discussed elsewhere herein.

The therapeutic/prophylactic purpose of such a method or use may be the modulation of the level of HIF α in a cell by modulation, e.g. disruption or interference, of the hydroxylation of HIF α , which may occur for example at proline 402, 564 or other proline residue. Hydroxylation of HIF α promotes pVHL binding which leads to ubiquitin dependent proteolysis of HIF α as described above.

The therapeutic/prophylactic purpose may be related to the treatment of a condition associated with reduced or suboptimal or increased HIF levels or activity, or conditions where an alteration in HIF levels or activity may be beneficial such as:

(i) ischaemic conditions, for example organ ischaemia, including coronary, cerebrovascular and peripheral vascular insufficiency. The therapy may be applied in two ways; following declared tissue damage, e.g. myocardial infarction (in order to

limit tissue damage), or prophylactically to prevent or ameliorate ischaemia, e.g. promotion of coronary collaterals in the treatment of angina.

(ii) wound healing and organ regeneration.

(iii) auto-, allo-, and xeno- transplantation.

5 (iv) systemic blood pressure.

(v) cancer; HIF α is commonly up-regulated in tumour cells and has major effects on tumour growth and angiogenesis.

(vi) inflammatory disorders.

(vii) pulmonary arterial blood pressure, neurodegenerative disease.

10 (viii) metabolic disorders, e.g. diabetes.

Modulating HIF prolyl hydroxylase activity in a person, an organ, or a group of cells may be exploited in different ways to obtain a therapeutic benefit:

(a) Non cell autonomous: The HIF system is used by cells to influence the production of substances which signal to other cells. These signals may then have effects at (i) a distant site (for example erythropoietin acts on the bone marrow) or (ii) locally (angiogenic growth factors increase the local formation of blood vessels). Manipulating non cell autonomous behaviour via altering hydroxylase activity is therefore useful in the treatment of anaemia, and local ischaemia, for example in the eye, brain, heart and limbs. Many other signals that are involved in aspects of physiological homeostasis may be, or are known to be, adjusted by HIF activation. Consequently altering HIF prolyl hydroxylase activity may be used to potentiate or initiate a helpful response for a therapeutic benefit, or to prevent or ameliorate a harmful response. For example, this approach can be used to alter appetite, or blood pressure in the systemic or pulmonary beds.

25 (b) Cell autonomous: the HIF system is also used by cells to regulate cellular metabolism, and decisions concerning differentiation, proliferation and apoptosis. Therefore manipulating the HIF system can be used to alter the viability and behaviour of cells. An increase in cell viability can be achieved by increasing HIF activation, for example in an ischaemic tissue. This approach can also be used in improving pancreatic beta cell viability as a way of ameliorating diabetes, or of improving the viability or function of a group or groups of neurons in Parkinson's

30

disease, motoneurone disease or forms of dementia. In a different approach, the HIF signal can be manipulated to prevent a group of cells proliferating, or to promote its death or differentiation. For example transient activation of the HIF system in a malignant tumour can be used to provoke death of a substantial number of tumour cells.

Pharmaceutical Compositions

In various further aspects, the present invention thus provides a pharmaceutical composition, medicament, drug or other composition for such a purpose, the composition comprising one or more compounds of formulae (A) to (F), or derivatives thereof, the use of such an composition in a method of medical treatment, a method comprising administration of such a composition to a patient, e.g. for treatment (which may include preventative treatment) of a medical condition as described above, use of such an agent compound or substance in the manufacture of a composition, medicament or drug for administration for any such purpose, e.g. for treatment of a condition as described herein, and a method of making a pharmaceutical composition comprising admixing such an agent, compound or substance with a pharmaceutically acceptable excipient, vehicle or carrier, and optionally other ingredients.

The agent may be used as sole active agent or in combination with one another or with any other active substance, e.g. for anti-tumour therapy another anti-tumour compound or therapy, such as radiotherapy or chemotherapy.

Whatever the agent used in a method of medical treatment of the present invention, administration is preferably in a "prophylactically effective amount" or a "therapeutically effective amount" (as the case may be, although prophylaxis may be considered therapy), this being sufficient to show benefit to the individual. The actual amount administered, and rate and time-course of administration, will depend on the nature and severity of what is being treated. Prescription of treatment, e.g. decisions on dosage etc, is within the responsibility of general practitioners and other medical doctors.

An agent or composition may be administered alone or in combination with

other treatments, either simultaneously or sequentially dependent upon the condition to be treated, e.g. as described above.

Pharmaceutical compositions according to the present invention, and for use in accordance with the present invention, may include, in addition to active ingredient, a pharmaceutically acceptable excipient, carrier, buffer, stabiliser or other materials well known to those skilled in the art. Such materials should be non-toxic and should not interfere with the efficacy of the active ingredient. The precise nature of the carrier or other material will depend on the route of administration, which may be oral, or by injection, e.g. cutaneous, subcutaneous or intravenous. The compositions will typically be sterile.

Pharmaceutical compositions for oral administration may be in tablet, capsule, powder or liquid form. A tablet may include a solid carrier such as gelatin or an adjuvant. Liquid pharmaceutical compositions generally include a liquid carrier such as water, petroleum, animal or vegetable oils, mineral oil or synthetic oil. Physiological saline solution, dextrose or other saccharide solution or glycols such as ethylene glycol, propylene glycol or polyethylene glycol may be included.

For intravenous, cutaneous or subcutaneous injection, or injection at the site of affliction, the active ingredient will be in the form of a parenterally acceptable aqueous solution which is pyrogen-free and has suitable pH, isotonicity and stability. Those of relevant skill in the art are well able to prepare suitable solutions using, for example, isotonic vehicles such as Sodium Chloride Injection, Ringer's Injection, Lactated Ringer's Injection. Preservatives, stabilisers, buffers, antioxidants and/or other additives may be included, as required.

Liposomes, particularly cationic liposomes, may be used in carrier formulations. Examples of techniques and protocols mentioned above can be found in Remington's Pharmaceutical Sciences, 16th edition, Osol, A. (ed), 1980.

The substance or composition may be administered in a localised manner to a particular site or may be delivered in a manner in which it targets particular cells or tissues, for example using intra-arterial stent based delivery.

Targeting therapies may be used to deliver the active substance more specifically to certain types of cell, by the use of targeting systems such as antibody

or cell specific ligands. Targeting may be desirable for a variety of reasons, for example if the agent is unacceptably toxic, or if it would otherwise require too high a dosage, or if it would not otherwise be able to enter the target cells.


5 The following Examples further illustrate the present invention.

Example 1

10 In vitro screening of potential inhibitors of HIF modification was performed using a capture assay. A Gal/HIF-1 α /VP16 fusion protein expressing HIF-1 α residues 549-582 was prepared by IVTT (see British Application No. 0118952.1) and used as a substrate in the assay. The unlabelled substrate was immunopurified on beads, washed, and aliquots incubated in the presence of RCC4 cell extract, with 100 μ M FeCl₂ and 2mM of the potential inhibitor. The inhibitors were either dissolved in DMSO or Tris as indicated. Controls, where no inhibitor but the equivalent amount of DMSO or Tris was added, were also performed. After washing,
15 the beads were assayed for their ability to interact with 35-S labelled pVHL IVTT. Hydroxylation of the fusion protein by HIF hydroxylase present in the cell extract leads to the ability to capture the labelled pVHL and the amount of labelled protein bound to the fusion protein can then be measured to determine relative HIF hydroxylase activity. Figures 1 to 5 show HIF hydroxylase activity in the presence of
20 a particular inhibitor relative to that seen in the absence of the inhibitor (the DMSO/Tris control).


CLAIMS

1. A compound of one of the formulae




- where each of R^1 and R^5 is independently H, OH, SH, a branched or straight C_1 to C_6 alkyl chain optionally containing 1 or more N, S, O or P chain atoms, which can be functionalised, any amino acid side chain, a 4 to 7 membered heterocyclic ring optionally containing 1 or 2 N, S, O or P atoms or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms which may be fused to another ring or a said alkyl chain substituted by a said aromatic ring, A^1 is CH_2 or O, and each of R^2 and R^3 is independently H, OH, a branched or straight C_1 to C_6 alkyl chain optionally containing 1 or more N, S, O or P chain atoms which can be functionalised, optionally with 1, 2, 3, 4 or 5 halo substitutions, a 4 to 7 membered heterocyclic ring optionally containing 1 or 2 N, S, O or P atoms, or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N, O or S atoms which may be fused to another ring or a said alkyl chain substituted by a said aromatic ring,

20



- 25 wherein R^2 is as defined above, --- is a single bond and T is CH_2 or $C=O$, or --- is a double bond and T is CH; A^2 is H or $-XCO_2R^4$; X is a single bond or a branched or straight C_1 to C_6 alkyl chain optionally containing 1 or more N, S, O or P chain atoms, and optionally substituted by halo, OH, OR^4 , NRR^2 or $NHCOR^4$ where R^2 , R^3 and R^4 are as defined above and R^4 represents H, a branched or straight chain C_1 to C_6 alkyl group, a 4 to 7 membered heterocyclic ring, optionally containing 1 or 2 N, S, O or P atoms, or a 5 or 6 membered aromatic ring, optionally containing 1 or 2 N,
- 30

O or S atoms, which may be fused to another ring,



5


where each X which may be the same or different is NH, NRⁿ, where Rⁿ is OH, a branched or straight C₁ to C₆ alkyl chain optionally containing 1 or more eg. 2 N, S, O or P chain atoms which can be functionalised, or O, each Y, which may be the same or different, is O or S and each R¹, which may be the same or different, is as defined above,

10




where m is 0 or 1, Q represents (CR¹R⁶)_xZ where x is 0, 1 or 2, R¹ is as defined above and R⁶ is as defined for R¹ and Z is P=O(OH)₂, B(OH)₂ or SO₃H, or a salt thereof, or

15



where each R¹, which are the same or different, is as defined above; R¹¹ represents OH or R¹⁰ NH where R¹⁰ is HO, R¹CO or HOOC(X)_x wherein R¹ is as defined above, x is 0 or 1 and X is R¹R¹C wherein each R¹, which are the same or different, is as defined above; or R¹⁰ is an amino acid residue H₂N (R¹R¹C) CO- wherein each R¹, which are the same or different, is as defined above; n is 1 or 2 and R¹² is H or straight or branched C₁ to C₆ alkyl; or a salt thereof,

25



wherein each of Z¹ and Z² is independently hydrogen, SH or an electron withdrawing group, and R¹² is as defined above, or a salt thereof for use in the treatment of a

30

- condition associated with increased or decreased HIF levels or activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.
2. A compound according to claim 1 which is of formula (A) where R¹ is aryloxymethyl, R² is hydrogen and R³ is hydrogen.
- 5 3. A compound according to claim 2 wherein R¹ is phenyloxymethyl, benzyloxymethyl or p-hydroxybenzylmethyl.
4. A compound according to claim 1 of formula (B) where X is a single bond or methyl, R² is H or phenyl alkyl and R⁴ is H or methyl.
5. A compound according to claim 1 of formula (C) wherein X is O and R¹ is H
10 or methyl.
6. A compound according to claim 1 of formula (D) wherein x is 1, and R¹ and R⁶ are both hydrogen.
7. A compound according to claim 1 of formula (E) wherein R¹ is H and R¹² is H or ethyl.
- 15 8. A compound according to claim 7 wherein R¹¹ represents R¹⁰ NH and R¹⁰ is an acyl group of a natural amino acid, acetyl or benzoyl.
9. A compound according to claim 7 wherein R¹¹ is HOOC(X)x.
10. Use of a compound as defined in claim 1 in the manufacture of a medicament for the treatment of a condition associated with increased or decreased HIF levels or
20 activity, or a condition in which an increase or decrease in HIF levels or activity may be beneficial.
11. Use according to claim 10 wherein the compound is as defined in any one of claims 2 to 9.
12. A pharmaceutical composition which comprises a compound as defined in
25 claim 1 together with a pharmaceutically acceptable excipient vehicle or carrier.
13. A composition according to claim 12 wherein the compound is as defined in any one of claims 2 to 9.

Figure 1




Figure 2




Figure 3




Figure 4





Figure 5



SEQUENCE LISTING

<110> ISIS INNOVATION LIMITED
 <120> HIF HYDROXYLASE INHIBITORS
 5 <130> N.85209A PEJ

 <160> 6
 <170> PatentIn version 3.1

 10 <210> 1
 <211> 2110
 <212> DNA
 <213> Homo sapiens
 <220>
 15 <221> CDS
 <222> (297)..(1517)
 <223>

 <400> 1
 20 gctttccctt gcctgcctgt ctctagtttc tctcacatcc cttttttttt tcctttctct 60
 agccaccctg aagggtccct tccaagccc ttagggaccg cagaggactt ggggaccagc 120
 aagcaacccc cagggcacga gaagagctct tgctgtctgc cctgcctcac cctgccccac 180
 accaggcccg gtggcccca gctgcatcaa gtggaggcgg aggaggaggc ggaggagggg 240
 ggcaccatgg gcccgggcgg tgccctccat gcccggggga tgaagacact gctgcc atg 299
 Met
 25 1
 gac agc ccg tgc cag ccg cag ccc cta agt cag gct ctc cct cag tta 347
 Asp Ser Pro Cys Gln Pro Gln Pro Leu Ser Gln Ala Leu Pro Gln Leu
 5 10 15
 30 cca ggg tct tgc tca gag ccc ttg gag cct gag cct ggc cgg gcc agg 395
 Pro Gly Ser Ser Ser Glu Pro Leu Glu Pro Glu Pro Gly Arg Ala Arg
 20 25 30
 atg gga gtg gag agt tac ctg ccc tgt ccc ctg ctc ccc tcc tac cac 443
 Met Gly Val Glu Ser Tyr Leu Pro Cys Pro Leu Leu Pro Ser Tyr His
 35 35 40 45
 tgt cca gga gtg cct agt gag gcc tgc gca ggg agt ggg acc ccc aga 491
 Cys Pro Gly Val Pro Ser Glu Ala Ser Ala Gly Ser Gly Thr Pro Arg
 50 55 60 65
 gcc aca gcc acc tct acc act gcc agc cct ctt cgg gac ggt ttt ggc 539
 Ala Thr Ala Thr Ser Thr Thr Ala Ser Pro Leu Arg Asp Gly Phe Gly
 40 70 75 80
 ggg cag gat ggt ggt gag ctg cgg ccg ctg cag agt gaa ggc gct gca 587
 Gly Gln Asp Gly Gly Glu Leu Arg Pro Leu Gln Ser Glu Gly Ala Ala
 85 90 95
 45 gcg ctg gtc acc aag ggg tgc cag cga ttg gca gcc cag ggc gca cgg 635
 Ala Leu Val Thr Lys Gly Cys Gln Arg Leu Ala Ala Gln Gly Ala Arg
 100 105 110
 cct gag gcc ccc aaa cgg aaa tgg gcc gag gat ggt ggg gat gcc cct 683
 Pro Glu Ala Pro Lys Arg Lys Trp Ala Glu Asp Gly Gly Asp Ala Pro

	115	120	125	
	tca ccc agc aaa cgg ccc tgg gcc agg caa gag aac cag gag gca gag			731
	Ser Pro Ser Lys Arg Pro Trp Ala Arg Gln Glu Asn Gln Glu Ala Glu			
	130	135	140	145
5	cgg gag ggt ggc atg agc tgc agc tgc agc agt ggc agt ggt gag gcc			779
	Arg Glu Gly Gly Met Ser Cys Ser Cys Ser Ser Gly Ser Gly Glu Ala			
	150	155	160	
	agt gct ggg ctg atg gag gag gcg ctg ccc tct gcg ccc gag cgc ctg			827
	Ser Ala Gly Leu Met Glu Glu Ala Leu Pro Ser Ala Pro Glu Arg Leu			
10	165	170	175	
	gcc ctg gac tat atc gtg ccc tgc atg cgg tac tac ggc atc tgc gtc			875
	Ala Leu Asp Tyr Ile Val Pro Cys Met Arg Tyr Tyr Gly Ile Cys Val			
	180	185	190	
	aag gac agc ttc ctg ggg gca gca ctg ggc ggt cgc gtg ctg gcc gag			923
15	Lys Asp Ser Phe Leu Gly Ala Ala Leu Gly Gly Arg Val Leu Ala Glu			
	195	200	205	
	gtg gag gcc ctc aaa cgg ggt ggg cgc ctg cga gac ggg cag cta gtg			971
	Val Glu Ala Leu Lys Arg Gly Gly Arg Leu Arg Asp Gly Gln Leu Val			
	210	215	220	225
20	agc cag agg gcg atc ccg ccg cgc agc atc cgt ggg gac cag att gcc			1019
	Ser Gln Arg Ala Ile Pro Pro Arg Ser Ile Arg Gly Asp Gln Ile Ala			
	230	235	240	
	tgg gtg gaa ggc cat gaa cca ggc tgt cga agc att ggt gcc ctc atg			1067
	Trp Val Glu Gly His Glu Pro Gly Cys Arg Ser Ile Gly Ala Leu Met			
25	245	250	255	
	gcc cat gtg gac gcc gtc atc cgc cac tgc gca ggg cgg ctg ggc agc			1115
	Ala His Val Asp Ala Val Ile Arg His Cys Ala Gly Arg Leu Gly Ser			
	260	265	270	
	tat gtc atc aac ggg cgc acc aag gcc atg gtg gcg tgt tac cca ggc			1163
30	Tyr Val Ile Asn Gly Arg Thr Lys Ala Met Val Ala Cys Tyr Pro Gly			
	275	280	285	
	aac ggg ctc ggg tac gta agg cac gtt gac aat ccc cac ggc gat ggg			1211
	Asn Gly Leu Gly Tyr Val Arg His Val Asp Asn Pro His Gly Asp Gly			
	290	295	300	305
35	cgc tgc atc acc tgt atc tat tac ctg aat cag aac tgg gac gtt aag			1259
	Arg Cys Ile Thr Cys Ile Tyr Tyr Leu Asn Gln Asn Trp Asp Val Lys			
	310	315	320	
	gtg cat ggc ggc ctg ctg cag atc ttc cct gag ggc cgg ccc gtg gta			1307
	Val His Gly Gly Leu Leu Gln Ile Phe Pro Glu Gly Arg Pro Val Val			
40	325	330	335	
	gcc aac atc gag cca ctc ttt gac cgg ttg ctc att ttc tgg tct gac			1355
	Ala Asn Ile Glu Pro Leu Phe Asp Arg Leu Leu Ile Phe Trp Ser Asp			
	340	345	350	
	cgg cgg aac ccc cac gag gtg aag cca gcc tat gcc acc agg tac gcc			1403
45	Arg Arg Asn Pro His Glu Val Lys Pro Ala Tyr Ala Thr Arg Tyr Ala			
	355	360	365	
	atc act gtc tgg tat ttt gat gcc aag gag cgg gca gca gcc aaa gac			1451
	Ile Thr Val Trp Tyr Phe Asp Ala Lys Glu Arg Ala Ala Ala Lys Asp			
	370	375	380	385

	aag tat cag cta gca tca gga cag aaa ggt gtc caa gta cct gta tca	1499
	Lys Tyr Gln Leu Ala Ser Gly Gln Lys Gly Val Gln Val Pro Val Ser	
	390 395 400	
5	cag ccg cct acg ccc acc tagtggccag tcccagagcc gcatggcaga	1547
	Gln Pro Pro Thr Pro Thr	
	405	
	cagcttaa at gacttcagga gagccctggg cctgtgctgg ctgctccttc cctgccaccg	1607
	ctgctgcttc tgactttgcc tctgtcctgc ctgggtgtgga gggctctgtc tgttctgag	1667
	gaccaaggag gagaagagac ctttctgccc ccatcatggg ggctgggggt gtcacctgga	1727
10	cagggggcag ccgtggaggc caccgttacc aactgaagct gggggcctgg gtcctaccct	1787
	gtctggtcat gacccatta ggtatggaga gctgggagga ggcattgtca cttcccacca	1847
	ggatgcagga cttgggggtg aggtgagtca tggcctcttg ctggcaatgg ggtgggagga	1907
	gtaccccaaa gtcctctcac tcctccagcc tggaatgtga agtgactccc caacccttt	1967
	ggcatggca ggcacctttt ggactgggct gccactgctt gggcagagta aaaggtgcca	2027
15	ggaggagcat ggggtgtgaa gtcctgtcag ccaagaaata aaagtttacc tcagagctgc	2087
	aaaaaaaa aaaaaaaaaa aaa	2110
	<210> 2	
	<211> 407	
20	<212> PRT	
	<213> Homo sapiens	
	<400> 2	
25	Met Asp Ser Pro Cys Gln Pro Gln Pro Leu Ser Gln Ala Leu Pro Gln	
	1 5 10 15	
	Leu Pro Gly Ser Ser Ser Glu Pro Leu Glu Pro Glu Pro Gly Arg Ala	
	20 25 30	
	Arg Met Gly Val Glu Ser Tyr Leu Pro Cys Pro Leu Leu Pro Ser Tyr	
	35 40 45	
30	His Cys Pro Gly Val Pro Ser Glu Ala Ser Ala Gly Ser Gly Thr Pro	
	50 55 60	
	Arg Ala Thr Ala Thr Ser Thr Thr Ala Ser Pro Leu Arg Asp Gly Phe	
	65 70 75 80	
	Gly Gly Gln Asp Gly Gly Glu Leu Arg Pro Leu Gln Ser Glu Gly Ala	
35	85 90 95	
	Ala Ala Leu Val Thr Lys Gly Cys Gln Arg Leu Ala Ala Gln Gly Ala	
	100 105 110	
	Arg Pro Glu Ala Pro Lys Arg Lys Trp Ala Glu Asp Gly Gly Asp Ala	
	115 120 125	
40	Pro Ser Pro Ser Lys Arg Pro Trp Ala Arg Gln Glu Asn Gln Glu Ala	
	130 135 140	
	Glu Arg Glu Gly Gly Met Ser Cys Ser Cys Ser Ser Gly Ser Gly Glu	
	145 150 155 160	
	Ala Ser Ala Gly Leu Met Glu Glu Ala Leu Pro Ser Ala Pro Glu Arg	
45	165 170 175	
	Leu Ala Leu Asp Tyr Ile Val Pro Cys Met Arg Tyr Tyr Gly Ile Cys	
	180 185 190	
	Val Lys Asp Ser Phe Leu Gly Ala Ala Leu Gly Gly Arg Val Leu Ala	
	195 200 205	

Glu Val Glu Ala Leu Lys Arg Gly Gly Arg Leu Arg Asp Gly Gln Leu
 210 215 220
 Val Ser Gln Arg Ala Ile Pro Pro Arg Ser Ile Arg Gly Asp Gln Ile
 225 230 235 240
 5 Ala Trp Val Glu Gly His Glu Pro Gly Cys Arg Ser Ile Gly Ala Leu
 245 250 255
 Met Ala His Val Asp Ala Val Ile Arg His Cys Ala Gly Arg Leu Gly
 260 265 270
 10 Ser Tyr Val Ile Asn Gly Arg Thr Lys Ala Met Val Ala Cys Tyr Pro
 275 280 285
 Gly Asn Gly Leu Gly Tyr Val Arg His Val Asp Asn Pro His Gly Asp
 290 295 300
 Gly Arg Cys Ile Thr Cys Ile Tyr Tyr Leu Asn Gln Asn Trp Asp Val
 305 310 315 320
 15 Lys Val His Gly Gly Leu Leu Gln Ile Phe Pro Glu Gly Arg Pro Val
 325 330 335
 Val Ala Asn Ile Glu Pro Leu Phe Asp Arg Leu Leu Ile Phe Trp Ser
 340 345 350
 Asp Arg Arg Asn Pro His Glu Val Lys Pro Ala Tyr Ala Thr Arg Tyr
 355 360 365
 20 Ala Ile Thr Val Trp Tyr Phe Asp Ala Lys Glu Arg Ala Ala Ala Lys
 370 375 380
 Asp Lys Tyr Gln Leu Ala Ser Gly Gln Lys Gly Val Gln Val Pro Val
 385 390 395 400
 25 Ser Gln Pro Pro Thr Pro Thr
 405

<210> 3
 <211> 5163
 30 <212> DNA
 <213> Homo sapiens
 <220>

<220>
 35 <221> CDS
 <222> (3157)..(4434)
 <223>

<400> 3
 40 ttaggggcag aaaaacattt gtaataatta atggctttga gagacacaag gctttgtttg 60
 cccagagta ttagttaacc cacctagtgc tcctaatacat acaatattaa ggattgggag 120
 ggacattcat tgcctcactc tctatttggt tcaccttctg taaaattggt agaataatag 180
 taccacttc atagcattgt atgatgatta aattgggtta tatttttaaa atgcttagaa 240
 cacagattgg gcacataaca gcaagcacca catgtgttta taagataaat tcctttgtgt 300
 45 tgccttccgt taaagttaa ataagtaaat aaataaataa atacttgcac gacattttga 360
 agtctctcta taacatctga gtaagtggcg gctgcgacaa tgctactgga gttccagaat 420
 cgtgttggtg acaagattgt tcaccagcat atggtgtggt gaaaactcac taatttgga 480
 ttagttcaga ttattaagcc tgaatagtg aaaatcctga aatcaaggat ctttggaact 540
 atttgaatc agtattttat attttctgt tgtattcatt aaagtgtgc aagtgttcta 600

	tttgatggat	taagtatatt	taggatatac	atgttcaatt	tgtgattttg	tataacttaat	660
	tggaacaaga	aagctaataa	aggttttgat	atggacatct	attcttttaa	gtaaacttca	720
	atgaaaatat	atgagtagag	catatagaga	tgtaataaat	ttgtggacac	accacagact	780
	gaaatagcaa	atttaaaaga	aattgttgga	agaatcaagt	gtttgtggaa	tgagtcctcc	840
5	tagtaaagtt	cctgctcttg	tgaataatta	agcctcatgt	ataattacta	tagcaaaagg	900
	aagcctaaga	agtattagac	tctacttgta	tttaaattac	attttacata	atttatgtgt	960
	atgaaaaatg	ttttaaatgc	ttattttcgt	aagccatgag	atagctcctt	tatattttaa	1020
	gaatttctga	attaatttgc	ttggatttta	ttagtgcaaa	tggcagagct	agcaattcct	1080
	ttttctgtgt	tcccattcca	tcctattcat	ccctctttta	ggaaactctg	aactctggat	1140
10	tgtccttggt	tacatacctg	cctcctgcat	tggactatgt	gtctctgagt	gtagtatgac	1200
	taattcattt	gtttgtcaag	gactctcaat	gcatttggtg	aacagcctaa	ttagtaatgt	1260
	ctgcaacaat	gacattttac	tgtatttaat	aaagctctgg	gaaagtagga	tacacataag	1320
	acaggtctag	gtctaaattc	tttacagaaa	cttggatttt	tagttcgggt	tgaatttga	1380
	agatgtgagt	atattttatct	cagtttccca	aaggacaagc	taattggaat	tatcatcctc	1440
15	tttcaattga	ttggatcccc	agaatgccat	ttacgcagtc	agcaggattt	tataacagtt	1500
	ttaaattctg	tatatattgat	gaagaggttt	tatatatttg	gattcaagcc	tctttttaaa	1560
	cttctacaat	atggtttaca	ataattcctt	atatcctgct	tttgaaatac	atattacaac	1620
	ttttaagtt	tggaggctta	tatttcaagg	actgaagtta	cagtatactc	aagtataaca	1680
	caagcctagc	accccacttt	ccacatagtg	ttcgataaag	attgataaac	tcgaaatcac	1740
20	agacctttta	attcttaaga	caaatagcag	cagaaagaaa	catctttggc	ttatttctgg	1800
	taagggtttt	atgctctgta	aaacaaagaa	ttgtattcat	ccgcgcagca	cagattctat	1860
	taaaaaataa	tgtgagagtc	gttaatgtag	tactgtcat	ttaccatcaa	aattcacttt	1920
	tcaggaataa	tcccatcagt	ttaaattgga	tattggaatg	agcattgatt	acatttaact	1980
	tggtagccca	aaatttcttc	atgggggttt	gaactcggcg	ggatttcaaa	ggttttaaaa	2040
25	atgagttttt	gatttttttt	aaaaccctca	aatttcatta	cctttaaaact	aggtcgaaac	2100
	ggggcgcaag	agatttgatt	aacaccatag	taatacttat	tttgttctta	accatttcag	2160
	ggcttcttga	aatagaggct	gtatgggtga	atggaaaaaa	cagccttgga	atctgggagc	2220
	ctgattcctg	gattcagtc	cagttttgcg	tgaccttggg	caagttactt	tacttctctg	2280
	aatttccgtt	tcctcctctg	caaaatgagg	atcgcaatag	ccaccttgca	accttgactg	2340
30	gagcgagcct	cgcacacccc	gcgccggcct	ggaggaagag	cagccatgat	tacgccgcct	2400
	tcgtccgct	acccgcttgc	ggctggcgcc	ctcctccagc	aggtgtaggc	gctgccgcgc	2460
	tgccccacgc	ctttccgccg	ctcgccggcc	tgccctcgg	cgtccccgag	gaggccgctg	2520
	cgggctgagg	tagcgcaccg	gcctctcgcc	gtcccagtc	ggtcccgggc	ggagggaaag	2580
	cgggcgaccc	acctccgagg	cagaagccga	ggcccggccc	cgccgagtc	ggaggagcgc	2640
35	aggcagcccc	cgcctcctcg	ccctcccccc	ggcctcccg	gccctccctc	cgccccctcc	2700
	gccctcgcgc	gccgcccgc	cgggtcgcgc	cggggccgtg	gtgtacgtgc	agagcgcgca	2760
	gagcgagtgg	cgcccgatg	ccctgcgctc	ctccacagcc	tgggccgggc	cgcccgggac	2820
	gctgaggcgg	cggcggcggc	cgagggggcc	ggtcttgccg	tccccaggcc	cgcgcgctg	2880
	agcccagggt	gccattcgcc	gcacaggccc	tattctctca	gccctcggcg	gcgatgaggc	2940
40	gctgaggcgg	ctgccggcgc	tgcgccggag	cttaggactc	ggaagcggcc	gggccgaggg	3000
	cgtgggggtg	cggcctccct	gaggcgaggg	tagcgggtgc	atggcgagc	aacggcccct	3060
	atctctctcc	ccgctcccca	gcctcgggcg	aggccgtccg	gccgtaccc	ctcctgctcg	3120
	gccgccgcag	tcgccgtcgc	gcgccgcgcc	gccgcc atg	gcc aat gac agc ggc		3174
				Met	Ala Asn Asp Ser Gly		
45				1	5		
	ggg ccc ggc	ggg ccg agc	ccg agc gag	cga gac	cgg cag tac	tgc gag	3222
	Gly Pro Gly	Gly Pro Ser	Pro Ser Glu	Arg Asp	Arg Gln Tyr	Cys Glu	
		10	15		20		
	ctg tgc ggg	aag atg gag	aac ctg ctg	cgc tgc	agc cgc tgc	cgc agc	3270

	Leu	Cys	Gly	Lys	Met	Glu	Asn	Leu	Leu	Arg	Cys	Ser	Arg	Cys	Arg	Ser	
		25					30					35					
	tcc	ttc	tac	tgc	tgc	aag	gag	cac	cag	cgt	cag	gac	tgg	aag	aag	cac	3318
	Ser	Phe	Tyr	Cys	Cys	Lys	Glu	His	Gln	Arg	Gln	Asp	Trp	Lys	Lys	His	
5		40					45					50					
	aag	ctc	gtg	tgc	cag	ggc	agc	gag	ggc	gcc	ctc	ggc	cac	gga	gtg	ggc	3366
	Lys	Leu	Val	Cys	Gln	Gly	Ser	Glu	Gly	Ala	Leu	Gly	His	Gly	Val	Gly	
	55					60					65				70		
	cca	cac	cag	cat	tcc	ggc	ccc	gcg	ccg	ccg	gct	gca	gtg	ccg	ccg	ccc	3414
10	Pro	His	Gln	His	Ser	Gly	Pro	Ala	Pro	Pro	Ala	Ala	Val	Pro	Pro	Pro	
					75					80					85		
	agg	gcc	ggg	gcc	cgg	gag	ccc	agg	aag	gca	gcg	gcg	cgc	cgg	gac	aac	3462
	Arg	Ala	Gly	Ala	Arg	Glu	Pro	Arg	Lys	Ala	Ala	Ala	Arg	Arg	Asp	Asn	
				90					95					100			
15	gcc	tcc	ggg	gac	gcg	gcc	aag	gga	aaa	gta	aag	gcc	aag	ccc	ccg	gcc	3510
	Ala	Ser	Gly	Asp	Ala	Ala	Lys	Gly	Lys	Val	Lys	Ala	Lys	Pro	Pro	Ala	
			105					110					115				
	gac	cca	gcg	gcg	gcc	gcg	tcg	ccg	tgt	cgt	gcg	gcc	gcc	ggc	ggc	cag	3558
	Asp	Pro	Ala	Ala	Ala	Ala	Ser	Pro	Cys	Arg	Ala	Ala	Ala	Gly	Gly	Gln	
20		120					125					130					
	ggc	tcg	gcg	gtg	gct	gcc	gaa	gcc	gag	ccc	ggc	aag	gag	gag	ccg	ccg	3606
	Gly	Ser	Ala	Val	Ala	Ala	Glu	Ala	Glu	Pro	Gly	Lys	Glu	Glu	Pro	Pro	
	135					140					145				150		
	gcc	cgc	tca	tcg	ctg	ttc	cag	gag	aag	gcg	aac	ctg	tac	ccc	cca	agc	3654
25	Ala	Arg	Ser	Ser	Leu	Phe	Gln	Glu	Lys	Ala	Asn	Leu	Tyr	Pro	Pro	Ser	
					155					160					165		
	aac	acg	ccc	ggg	gat	gcg	ctg	agc	ccc	ggc	ggc	ggc	ctg	cgg	ccc	aac	3702
	Asn	Thr	Pro	Gly	Asp	Ala	Leu	Ser	Pro	Gly	Gly	Gly	Leu	Arg	Pro	Asn	
				170					175					180			
30	ggg	cag	acg	aag	ccc	ctg	ccg	gcg	ctg	aag	ctg	gcg	ctc	gag	tac	atc	3750
	Gly	Gln	Thr	Lys	Pro	Leu	Pro	Ala	Leu	Lys	Leu	Ala	Leu	Glu	Tyr	Ile	
			185					190					195				
	gtg	ccg	tgc	atg	aac	aag	cac	ggc	atc	tgt	gtg	gtg	gac	gac	ttc	ctc	3798
	Val	Pro	Cys	Met	Asn	Lys	His	Gly	Ile	Cys	Val	Val	Asp	Asp	Phe	Leu	
35		200					205					210					
	ggc	aag	gag	acc	gga	cag	cag	atc	ggc	gac	gag	gtg	cgc	gcc	ctg	cac	3846
	Gly	Lys	Glu	Thr	Gly	Gln	Gln	Ile	Gly	Asp	Glu	Val	Arg	Ala	Leu	His	
	215					220					225				230		
	gac	acc	ggg	aag	ttc	acg	gac	ggg	cag	ctg	gtc	agc	cag	aag	agt	gac	3894
40	Asp	Thr	Gly	Lys	Phe	Thr	Asp	Gly	Gln	Leu	Val	Ser	Gln	Lys	Ser	Asp	
					235					240					245		
	tcg	tcc	aag	gac	atc	cga	ggc	gat	aag	atc	acc	tgg	atc	gag	ggc	aag	3942
	Ser	Ser	Lys	Asp	Ile	Arg	Gly	Asp	Lys	Ile	Thr	Trp	Ile	Glu	Gly	Lys	
				250					255					260			
45	gag	ccc	ggc	tgc	gaa	acc	att	ggg	ctg	ctc	atg	agc	agc	atg	gac	gac	3990
	Glu	Pro	Gly	Cys	Glu	Thr	Ile	Gly	Leu	Leu	Met	Ser	Ser	Met	Asp	Asp	
			265					270						275			
	ctg	ata	cgc	cac	tgt	aac	ggg	aag	ctg	ggc	agc	tac	aaa	atc	aat	ggc	4038
	Leu	Ile	Arg	His	Cys	Asn	Gly	Lys	Leu	Gly	Ser	Tyr	Lys	Ile	Asn	Gly	

	280	285	290	
	cgg acg aaa gcc atg gtt gct tgt tat ccg ggc aat gga acg ggt tat	4086		
	Arg Thr Lys Ala Met Val Ala Cys Tyr Pro Gly Asn Gly Thr Gly Tyr			
	295 300 305 310			
5	gta cgt cat gtt gat aat cca aat gga gat gga aga tgt gtg aca tgt	4134		
	Val Arg His Val Asp Asn Pro Asn Gly Asp Gly Arg Cys Val Thr Cys			
	315 320 325			
	ata tat tat ctt aat aaa gac tgg gat gcc aag gta agt gga ggt ata	4182		
	Ile Tyr Tyr Leu Asn Lys Asp Trp Asp Ala Lys Val Ser Gly Gly Ile			
10	330 335 340			
	ctt cga att ttt cca gaa ggc aaa gcc cag ttt gct gac att gaa ccc	4230		
	Leu Arg Ile Phe Pro Glu Gly Lys Ala Gln Phe Ala Asp Ile Glu Pro			
	345 350 355			
	aaa ttt gat aga ctg ctg ttt ttc tgg tct gac cgt cgc aac cct cat	4278		
15	Lys Phe Asp Arg Leu Leu Phe Phe Trp Ser Asp Arg Arg Asn Pro His			
	360 365 370			
	gaa gta caa cca gca tat gct aca agg tac gca ata act gtt tgg tat	4326		
	Glu Val Gln Pro Ala Tyr Ala Thr Arg Tyr Ala Ile Thr Val Trp Tyr			
	375 380 385 390			
20	ttt gat gca gat gag aga gca cga gct aaa gta aaa tat cta aca ggt	4374		
	Phe Asp Ala Asp Glu Arg Ala Arg Ala Lys Val Lys Tyr Leu Thr Gly			
	395 400 405			
	gaa aaa ggt gtg agg gtt gaa ctc aat aaa cct tca gat tcg gtc ggt	4422		
	Glu Lys Gly Val Arg Val Glu Leu Asn Lys Pro Ser Asp Ser Val Gly			
25	410 415 420			
	aaa gac gtc ttc tagagccttt gatccagcaa tacccactt cacctacaat	4474		
	Lys Asp Val Phe			
	425			
	attgttaact atttgtaaact ttgtgaatac gaataaatgg gataaagaaa aatagacaac	4534		
30	cagttcgcat ttttaataagg aaacagaaac aactttttgt gttgcatcaa acagaagatt	4594		
	ttgactgctg tgactttgta ctgcatgac aacttcaaact ctgtgattgc ttacaggagg	4654		
	aagataagct actaattgaa aatgggtttt acatctggat atgaaataag tgccctgtgt	4714		
	agaatttttt tcattcttat attttgccag atctgttatc tagctgagtt catttcatct	4774		
	ctcccttttt tatatcaagt ttgaatttgg gataattttt ctatattagg tacaatttat	4834		
35	ctaaactgaa ttgagaaaaa attacagtat tattcctcaa aataacatca atctattttt	4894		
	gtaaacctgt tcatactatt aaattttgcc ctaaaagacc tcttaataat gattgttgcc	4954		
	agtgactgat gattaatttt attttactta aaataagaaa aggagcactt taattacaac	5014		
	tgaaaaatca gattgttttg cagtccttcc ttactactaat ttgaactctt aaagattgct	5074		
	gctttttttt tgacattgtc aataacgaaa cctaattgta aaacagtcac catttactac	5134		
40	caataacttt tagttaatgt tttaacaagg	5163		
	<210> 4			
	<211> 426			
	<212> PRT			
45	<213> Homo sapiens			
	<400> 4			
	Met Ala Asn Asp Ser Gly Gly Pro Gly Gly Pro Ser Pro Ser Glu Arg			
	1 5 10 15			

	Asp	Arg	Gln	Tyr	Cys	Glu	Leu	Cys	Gly	Lys	Met	Glu	Asn	Leu	Leu	Arg
			20						25				30			
	Cys	Ser	Arg	Cys	Arg	Ser	Ser	Phe	Tyr	Cys	Cys	Lys	Glu	His	Gln	Arg
			35					40					45			
5	Gln	Asp	Trp	Lys	Lys	His	Lys	Leu	Val	Cys	Gln	Gly	Ser	Glu	Gly	Ala
		50					55					60				
	Leu	Gly	His	Gly	Val	Gly	Pro	His	Gln	His	Ser	Gly	Pro	Ala	Pro	Pro
	65					70					75				80	
	Ala	Ala	Val	Pro	Pro	Pro	Arg	Ala	Gly	Ala	Arg	Glu	Pro	Arg	Lys	Ala
10					85					90					95	
	Ala	Ala	Arg	Arg	Asp	Asn	Ala	Ser	Gly	Asp	Ala	Ala	Lys	Gly	Lys	Val
				100					105					110		
	Lys	Ala	Lys	Pro	Pro	Ala	Asp	Pro	Ala	Ala	Ala	Ala	Ser	Pro	Cys	Arg
		115						120					125			
15	Ala	Ala	Ala	Gly	Gly	Gln	Gly	Ser	Ala	Val	Ala	Ala	Glu	Ala	Glu	Pro
		130					135					140				
	Gly	Lys	Glu	Glu	Pro	Pro	Ala	Arg	Ser	Ser	Leu	Phe	Gln	Glu	Lys	Ala
	145					150					155				160	
	Asn	Leu	Tyr	Pro	Pro	Ser	Asn	Thr	Pro	Gly	Asp	Ala	Leu	Ser	Pro	Gly
20					165					170					175	
	Gly	Gly	Leu	Arg	Pro	Asn	Gly	Gln	Thr	Lys	Pro	Leu	Pro	Ala	Leu	Lys
			180					185						190		
	Leu	Ala	Leu	Glu	Tyr	Ile	Val	Pro	Cys	Met	Asn	Lys	His	Gly	Ile	Cys
		195						200					205			
25	Val	Val	Asp	Asp	Phe	Leu	Gly	Lys	Glu	Thr	Gly	Gln	Gln	Ile	Gly	Asp
		210					215					220				
	Glu	Val	Arg	Ala	Leu	His	Asp	Thr	Gly	Lys	Phe	Thr	Asp	Gly	Gln	Leu
		225				230					235				240	
	Val	Ser	Gln	Lys	Ser	Asp	Ser	Ser	Lys	Asp	Ile	Arg	Gly	Asp	Lys	Ile
30					245					250					255	
	Thr	Trp	Ile	Glu	Gly	Lys	Glu	Pro	Gly	Cys	Glu	Thr	Ile	Gly	Leu	Leu
			260					265						270		
	Met	Ser	Ser	Met	Asp	Asp	Leu	Ile	Arg	His	Cys	Asn	Gly	Lys	Leu	Gly
		275						280					285			
35	Ser	Tyr	Lys	Ile	Asn	Gly	Arg	Thr	Lys	Ala	Met	Val	Ala	Cys	Tyr	Pro
		290					295					300				
	Gly	Asn	Gly	Thr	Gly	Tyr	Val	Arg	His	Val	Asp	Asn	Pro	Asn	Gly	Asp
		305				310					315				320	
	Gly	Arg	Cys	Val	Thr	Cys	Ile	Tyr	Tyr	Leu	Asn	Lys	Asp	Trp	Asp	Ala
40					325					330					335	
	Lys	Val	Ser	Gly	Gly	Ile	Leu	Arg	Ile	Phe	Pro	Glu	Gly	Lys	Ala	Gln
				340					345					350		
	Phe	Ala	Asp	Ile	Glu	Pro	Lys	Phe	Asp	Arg	Leu	Leu	Phe	Phe	Trp	Ser
		355						360					365			
45	Asp	Arg	Arg	Asn	Pro	His	Glu	Val	Gln	Pro	Ala	Tyr	Ala	Thr	Arg	Tyr
		370					375					380				
	Ala	Ile	Thr	Val	Trp	Tyr	Phe	Asp	Ala	Asp	Glu	Arg	Ala	Arg	Ala	Lys
		385				390					395				400	
	Val	Lys	Tyr	Leu	Thr	Gly	Glu	Lys	Gly	Val	Arg	Val	Glu	Leu	Asn	Lys

	aag aat tgg gat gcc aag cta cat ggt ggg atc ctg cgg ata ttt cca	833
	Lys Asn Trp Asp Ala Lys Leu His Gly Gly Ile Leu Arg Ile Phe Pro	
	155 160 165	
5	gag ggg aaa tca ttc ata gca gat gtg gag ccc att ttt gac aga ctc	881
	Glu Gly Lys Ser Phe Ile Ala Asp Val Glu Pro Ile Phe Asp Arg Leu	
	170 175 180 185	
	ctg ttc ttc tgg tca gat cgt agg aac cca cac gaa gtg cag ccc tct	929
	Leu Phe Phe Trp Ser Asp Arg Arg Asn Pro His Glu Val Gln Pro Ser	
	190 195 200	
10	tac gca acc aga tat gct atg act gtc tgg tac ttt gat gct gaa gaa	977
	Tyr Ala Thr Arg Tyr Ala Met Thr Val Trp Tyr Phe Asp Ala Glu Glu	
	205 210 215	
	agg gca gaa gcc aaa aag aaa ttc agg aat tta act agg aaa act gaa	1025
	Arg Ala Glu Ala Lys Lys Lys Phe Arg Asn Leu Thr Arg Lys Thr Glu	
15	220 225 230	
	tct gcc ctc act gaa gac tgaccgtgct ctgaaatctg ctggccttgt	1073
	Ser Ala Leu Thr Glu Asp	
	235	
20	tcattttagt aacggttcct gaattctctt aaattctttg agatccaaag atggcctctt	1133
	cagtgcacaac aatctccctg ctacttcttg catccttcac atccctgtct tgtgtgtggt	1193
	acttcatgtt ttcttgccaa gactgtgttg atcttcagat actctctttg ccagatgaag	1253
	ttatttgcta actccagaaa ttcttgccaa catcctactc ggccagcggg ttacctgata	1313
	gattcggtaa tactatcaag agaagagcct aggagcacag cgagggaatg aaccttactt	1373
	gcactttatg tatacttcct gatttgaaag gaggagggtt gaaaagaaaa aaatggaggt	1433
25	ggtagatgcc acagagaggc atcacggaag ccttaacagc aggaacaga gaaatttgtg	1493
	tcatctgaac aatttccaga tgttcttaat ccagggtgtg tgggggttct ggagaattat	1553
	cacaacctaa tgacattaat acctctagaa agggctgctg tcatagttaa caatttataa	1613
	gtgtcccatg gggcagacac tccttttttc ccagtcctgc aacctggatt ttctgcctca	1673
	gctccatttt gctgaaaata atgactttct gaataaagat ggcaacacaa ttttttctcc	1733
30	attttcagtt cttacctggg aacctaatc cccagaagct aaaaaactag acattagtgtg	1793
	ttttggttgc tttgttgaa tggaaattaa atttaaatga aaggaaaaat atatccctgg	1853
	tagttttgtg ttaaccactg ataactgtgg aaagagctag gtctactgat atacaataaa	1913
	catgtgtgca tcttgaacaa tttgagaggg gagggtgagt tggaaatgtg ggtgttcctg	1973
	tttttttttt tttttttttt tttttttagt ttcccttttt aatgagctca ccctttaaca	2033
35	caaaaaaagc aggggtgatgt attttaaaaa aggaagtgga aataaaaaaa tctcaaagct	2093
	atttgagttc tcgtctgtcc cttagcgtct ttcttcagct cacttggctc tctagatcca	2153
	ctgtggttgg cagtatgacc agaatcatgg aacttgctag aactgtggaa gcttctactc	2213
	ctgcagtaag cacagatcgc actgcctcaa taacttggtg ttgagcacgt attttgcaaa	2273
	agctactttt cctagttttc agtattactt tcatgtttta aaaatccctt taatttcttg	2333
40	cttgaaaatc ccatgaacat taaagagcca gaaatatttt cctttgttat gtacggatat	2393
	atatatatat atagtcttcc aagatagaag ttactttttt cctcttcttg ttttgaaaa	2453
	tttccagata agacatgtca ccattaatc tcaacgactg ctctattttg ttgtacggtg	2513
	atagttatca ctttctaaat tactatgtaa ttactcact tattatgttt attgtcttgt	2573
	atcctttctc tggagtgtaa gcacaatgaa gacaggaatt ttgtatat tttaaccaatg	2633
45	caacatactc tcagcaccta aaatagtgcc gggaacatag taagggtcgt gtaaatactt	2693
	gttgaataaaa ctacgtctcc tacattagca ttctaaaaaa aaaaaaaaaa aaaaaaaaaa	2753
	aaaaaaaaaa aaaaaaag	2770

<211> 239
 <212> PRT
 <213> Homo sapiens
 <400> 6

5 Met Pro Leu Gly His Ile Met Arg Leu Asp Leu Glu Lys Ile Ala Leu
 1 5 10 15
 Glu Tyr Ile Val Pro Cys Leu His Glu Val Gly Phe Cys Tyr Leu Asp
 20 25 30
 10 Asn Phe Leu Gly Glu Val Val Gly Asp Cys Val Leu Glu Arg Val Lys
 35 40 45
 Gln Leu His Cys Thr Gly Ala Leu Arg Asp Gly Gln Leu Ala Gly Pro
 50 55 60
 Arg Ala Gly Val Ser Lys Arg His Leu Arg Gly Asp Gln Ile Thr Trp
 15 65 70 75 80
 Ile Gly Gly Asn Glu Glu Gly Cys Glu Ala Ile Ser Phe Leu Leu Ser
 85 90 95
 Leu Ile Asp Arg Leu Val Leu Tyr Cys Gly Ser Arg Leu Gly Lys Tyr
 100 105 110
 20 Tyr Val Lys Glu Arg Ser Lys Ala Met Val Ala Cys Tyr Pro Gly Asn
 115 120 125
 Gly Thr Gly Tyr Val Arg His Val Asp Asn Pro Asn Gly Asp Gly Arg
 130 135 140
 Cys Ile Thr Cys Ile Tyr Tyr Leu Asn Lys Asn Trp Asp Ala Lys Leu
 25 145 150 155 160
 His Gly Gly Ile Leu Arg Ile Phe Pro Glu Gly Lys Ser Phe Ile Ala
 165 170 175
 Asp Val Glu Pro Ile Phe Asp Arg Leu Leu Phe Phe Trp Ser Asp Arg
 180 185 190
 30 Arg Asn Pro His Glu Val Gln Pro Ser Tyr Ala Thr Arg Tyr Ala Met
 195 200 205
 Thr Val Trp Tyr Phe Asp Ala Glu Glu Arg Ala Glu Ala Lys Lys Lys
 210 215 220
 Phe Arg Asn Leu Thr Arg Lys Thr Glu Ser Ala Leu Thr Glu Asp
 35 225 230 235